IMMUNE CHECKPOINT INHIBITOR
The present invention relates to therapeutic antibodies, or antigen-binding portions thereof, for use in the treatment of cancer and infectious disease. Specifically, the present invention relates to therapeutic antibodies, or antigen-binding portions thereof, that target the programmed death-ligand...
Saved in:
Main Authors | , , , |
---|---|
Format | Patent |
Language | English French |
Published |
12.05.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The present invention relates to therapeutic antibodies, or antigen-binding portions thereof, for use in the treatment of cancer and infectious disease. Specifically, the present invention relates to therapeutic antibodies, or antigen-binding portions thereof, that target the programmed death-ligand 1 polypeptide. The present invention also relates to pharmaceutical compositions comprising said therapeutic antibody, or antigen-binding portions thereof.
La présente invention porte sur des anticorps thérapeutiques, ou des parties de liaison à l'antigène associées, destinés à être utilisés dans le traitement du cancer et de maladies infectieuses. La présente invention porte plus particulièrement sur des anticorps thérapeutiques, ou des parties de liaison à l'antigène associées, qui ciblent le polypeptide de ligand de mort programmée 1. La présente invention porte également sur des compositions pharmaceutiques comprenant ledit anticorps thérapeutique, ou des parties de liaison à l'antigène associées. |
---|---|
AbstractList | The present invention relates to therapeutic antibodies, or antigen-binding portions thereof, for use in the treatment of cancer and infectious disease. Specifically, the present invention relates to therapeutic antibodies, or antigen-binding portions thereof, that target the programmed death-ligand 1 polypeptide. The present invention also relates to pharmaceutical compositions comprising said therapeutic antibody, or antigen-binding portions thereof.
La présente invention porte sur des anticorps thérapeutiques, ou des parties de liaison à l'antigène associées, destinés à être utilisés dans le traitement du cancer et de maladies infectieuses. La présente invention porte plus particulièrement sur des anticorps thérapeutiques, ou des parties de liaison à l'antigène associées, qui ciblent le polypeptide de ligand de mort programmée 1. La présente invention porte également sur des compositions pharmaceutiques comprenant ledit anticorps thérapeutique, ou des parties de liaison à l'antigène associées. |
Author | SCHON, Shirley LAMONT, John DUNLOP, Marshall FITZGERALD, Peter |
Author_xml | – fullname: DUNLOP, Marshall – fullname: FITZGERALD, Peter – fullname: SCHON, Shirley – fullname: LAMONT, John |
BookMark | eNrjYmDJy89L5WSQ9vT1DfVzVXD2cHX2DvD39AtR8PTz8HTyDPEP4mFgTUvMKU7lhdLcDMpuriHOHrqpBfnxqcUFicmpeakl8eH-RgZGRgaWZibmBo6GxsSpAgC3ZCNL |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences |
DocumentTitleAlternate | INHIBITEUR DE POINT DE CONTRÔLE IMMUNITAIRE |
ExternalDocumentID | WO2022096470A1 |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_WO2022096470A13 |
IEDL.DBID | EVB |
IngestDate | Fri Jul 19 12:48:53 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | English French |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_WO2022096470A13 |
Notes | Application Number: WO2021EP80423 |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220512&DB=EPODOC&CC=WO&NR=2022096470A1 |
ParticipantIDs | epo_espacenet_WO2022096470A1 |
PublicationCentury | 2000 |
PublicationDate | 20220512 |
PublicationDateYYYYMMDD | 2022-05-12 |
PublicationDate_xml | – month: 05 year: 2022 text: 20220512 day: 12 |
PublicationDecade | 2020 |
PublicationYear | 2022 |
RelatedCompanies | RANDOX LABORATORIES LTD |
RelatedCompanies_xml | – name: RANDOX LABORATORIES LTD |
Score | 3.4042282 |
Snippet | The present invention relates to therapeutic antibodies, or antigen-binding portions thereof, for use in the treatment of cancer and infectious disease.... |
SourceID | epo |
SourceType | Open Access Repository |
SubjectTerms | CHEMISTRY METALLURGY ORGANIC CHEMISTRY PEPTIDES |
Title | IMMUNE CHECKPOINT INHIBITOR |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220512&DB=EPODOC&locale=&CC=WO&NR=2022096470A1 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwY2BQsTCwSDQ3MjbVBZ1VpWuSbJGsa2GYlqqbbJRmkGKSCKyxjEEbnH39zDxCTbwiTCOYGHJge2HA54SWgw9HBOaoZGB-LwGX1wWIQSwX8NrKYv2kTKBQvr1biK2LGrR3DNo1amik5uJk6xrg7-LvrObsDOy3qfkFQeRAuy4NHIF9JVZQQxp00r5rmBNoX0oBcqXiJsjAFgA0L69EiIEpNU-YgdMZdveaMAOHL3TKG8iE5r5iEQZpT1_fUD9XBWcPV2fvAH9PvxAFTz8PTyfPEP8gUQZlN9cQZw9doC3xcE_Fh_sjO8lYjIEF2N1PlWBQME0EdlqAHbE0S7NEYFslLSnN3NQoKdE81SA1KSXFLE2SQQafSVL4paUZuEBc0Py3oZEMA0tJUWmqLLBaLUmSA4cGANcDdy0 |
link.rule.ids | 230,309,786,891,25594,76903 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfZ1bS8MwFMcPY4rzTaeibmpB6Vux99aHITZtadx6YXS6t9ErCDKHq_j1PYmd7mlvIQeSJnBy8mvyPwG4s2U7s1TNkFiuKkkv7EKylbqSCrWWSz3DiKUxgXMYmcFMf54b8w68b7QwPE_oN0-OiB5VoL83fL1e_f_EcvndyvV9_oZVH49-OnLFlo6ZalRRRdcZeUnsxkQkBLlNjKa_Nqa6lJ-QlfYshEIOSy8O06WstoOKfwT7Cba3bI6hUy370CObt9f6cBC2R95YbL1vfQIDGoazyBNI4JFxEtMoFWgUUIem8fQUbn0vJYGEvSz-BrV4jbc_STuDLuJ-dQ6CkSG0IIjVD2aGe5U6ry1DzTOrkqu8LM36Aoa7Wrrcbb6BXpCGk8WERuMBHDITOwtX1CF0m8-v6gpDbJNf85n5AY5tehc |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=IMMUNE+CHECKPOINT+INHIBITOR&rft.inventor=DUNLOP%2C+Marshall&rft.inventor=FITZGERALD%2C+Peter&rft.inventor=SCHON%2C+Shirley&rft.inventor=LAMONT%2C+John&rft.date=2022-05-12&rft.externalDBID=A1&rft.externalDocID=WO2022096470A1 |